PodcastsCienciasThe Patient Signal

The Patient Signal

Stan Berteloot
The Patient Signal
Último episodio

42 episodios

  • The Patient Signal

    Heart Pump Trials Question Routine Use; Caris Detect Advances; Genomic Testing Tackles Disparities

    01/04/2026 | 3 min
    In this episode, we delve into recent findings from the American College of Cardiology’s annual meeting, where Johnson & Johnson's Impella heart pump was shown to offer no patient benefit in two major trials. The CHIP-BCIS3 trial indicated no reduction in adverse events during complex heart procedures, while the STEMI-DTU trial found no improvement for heart attack patients without cardiogenic shock. These results suggest a need for more selective use of mechanical circulatory support despite FDA approval for high-risk PCI.

    Next, we discuss Caris Life Sciences' completion of the Achieve 1 Study, which confirms the effectiveness of its Caris Detect multi-cancer early detection test. The study highlights the superior sensitivity and specificity of Whole Genome Sequencing, with impressive results across various cancer stages, supporting Caris' comprehensive genomic approach to cancer detection.

    Meanwhile, a study published in npj Breast Cancer reveals that genomic testing could help address racial disparities in breast cancer survival rates between Black and white women in the US. By using genomic tests from Agendia, the study found that personalized treatment based on genomic results led to similar outcomes for both groups, emphasizing the need for personalized care beyond traditional clinical markers.

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    📚 Sources:

    https://www.medtechdive.com/news/johnson-jnj-impella-heart-pump-ACC-no-patient-benefit-2-trials/816332/

    https://www.biospace.com/press-releases/caris-life-sciences-finalizes-achieve-1-study-results-reinforcing-the-superior-sensitivity-and-specificity-of-caris-detect/

    https://pharmaphorum.com/news/dna-testing-can-help-right-racial-imbalance-breast-cancer
  • The Patient Signal

    UCSB's MRI Breakthrough, Labcorp's Expansion, AI in Genomics, UK Drug Pathway, Ohio's Biomanufacturing Boost, Blackstone's Record Fund, IO Biotech Bankruptcy

    31/03/2026 | 8 min
    In this episode, we explore groundbreaking developments in the life sciences and healthcare sectors. Researchers at the University of California, Santa Barbara, have unveiled a genetic sensor that enhances MRI capabilities to image molecular-level changes, potentially revolutionizing disease study and diagnostics. Labcorp expands its diagnostic testing reach by acquiring pathology reference lab assets in New York, aiming for improved service delivery. Mount Sinai Health System, Nvidia, and ARC Innovation Center collaborate to use AI in decoding the human genome, advancing personalized medicine. The UK's MHRA and NICE streamline drug licensing and reimbursement processes to expedite patient access to new medicines. Ohio invests in a biomanufacturing workforce initiative, establishing a training center to boost the state's life sciences sector. Blackstone Life Sciences raises a record $6.3 billion fund to support biotech and pharmaceutical advancements. Lastly, IO Biotech files for bankruptcy after the FDA rejects its lead cancer vaccine candidate, highlighting the challenges in biotech innovation.

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    📚 Sources:

    https://www.futurity.org/mri-genetic-sensor-3328112/

    https://www.medtechdive.com/news/labcorp-closes-acquisition-new-york-pathology-reference-lab-assets/815384/

    https://www.mobihealthnews.com/video/nvidia-arc-mount-sinai-decode-human-genome

    https://pharmaphorum.com/news/first-mhranice-aligned-guidance-due-june

    https://www.genengnews.com/topics/bioprocessing/ohio-life-science-training-center-to-be-based-in-new-albany-international-business-park/

    https://endpoints.news/blackstone-raises-6-3b-life-sciences-fund-in-record-fundraising-haul/

    https://www.fiercebiotech.com/biotech/after-reeling-fda-refusal-io-biotech-surrenders-bankruptcy
  • The Patient Signal

    Unlocking Biotech's Future: AI, Atrandi's Innovations, and Generative AI in Drug Discovery

    13/02/2026 | 5 min
    In this episode, we delve into the transformative power of the data multiplier effect in the biotech sector, as reported by Fierce Biotech. By integrating expertise, monitoring systems, and AI, organizations can enhance the value of data, driving innovation and efficiency. This synergy allows for precise data analysis, improved decision-making, and accelerated R&D processes, crucial for breakthroughs in medical research and patient care.

    Next, we highlight Atrandi Biosciences' latest advancements in single-cell analysis, set to be presented at the SLAS2026 International Conference. Their Semi-Permeable Capsule technology and Phyx platform, which uses AI to enrich biological samples, promise to streamline complex workflows and make biological data more accessible to researchers.

    Meanwhile, life sciences leaders are embedding AI into their operations, shifting from a competitive advantage to a business necessity. AI is enhancing the identification of key opinion leaders and transforming commercial functions with timely insights, paving the way for future innovations.

    Generative AI is revolutionizing drug discovery by designing antibodies for G-protein coupled receptors, crucial in cellular communication. This technology promises to shorten discovery timelines and improve success rates across various conditions, though further advancements are needed.

    Finally, a Google Cloud survey reveals that AI is increasingly used in life sciences and healthcare for marketing, tech support, and productivity, with significant returns on investment. Despite regulatory challenges, AI is transforming drug development, emphasizing trust and traceability in its applications.

    Join Stan Berteloot, a French-American journalist and AI expert, as he navigates these cutting-edge developments in the biotech and life sciences sectors.

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    📚 Sources:

    https://www.fiercebiotech.com/sponsored/data-multiplier-effect-when-expertise-monitoring-systems-and-ai-align

    https://www.biospace.com/press-releases/atrandi-biosciences-brings-single-cell-direct-multiomics-technology-to-slas-2026-conference

    https://www.pharmexec.com/view/bridging-the-data-gap-how-digital-behavioral-insights-can-transform-hcp-targeting-in-specialty-care

    https://pharmaphorum.com/digital/how-genai-cracking-toughest-targets-drug-discovery

    https://www.genengnews.com/topics/artificial-intelligence/google-cloud-survey-life-sciences-leaders-find-roi-in-agentic-ai/
  • The Patient Signal

    2026 MedTech M&A Surge, Nona's Immunology Push, Stellaromics' Brain Research, and AI in Biotech

    30/01/2026 | 7 min
    In this episode, we explore the dynamic landscape of the medical device industry as it heads into 2026, with mergers and acquisitions taking center stage. We discuss Boston Scientific's significant acquisition of Penumbra and the challenges posed by expiring Affordable Care Act subsidies and tariffs. We also delve into the ongoing negotiations for the Medical Device User Fee Amendments and the competitive field of surgical robotics.

    Next, we highlight Nona Biosciences' co-founding of the Innovative Alliance for Translational Medicine in Immunological Diseases, aiming to advance research and clinical trials in immunological diseases.

    We then turn to Stellaromics' expansion of its Pyxa™ 3D spatial transcriptomics program, now installed at Emory University, to enhance research into RNA regulation in neurodegenerative diseases.

    Meanwhile, a collaboration in Taiwan has developed an exosome-based drug delivery platform for Parkinson's disease, showing promise in preclinical studies.

    In other news, the U.S. Department of Health and Human Services has issued new guidance to reduce prescription drug prices through Direct-to-Consumer programs, aiming to make medications more affordable.

    We also discuss the biotech industry's challenge with AI-driven medical breakthroughs, emphasizing the need for accessible AI infrastructure to ensure diverse innovation.

    Finally, BioMed X partners with Barbados and the EU to launch a project improving AI-based early diabetic kidney disease modeling, focusing on the Barbadian population's health challenges.

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    📚 Sources:

    https://www.medtechdive.com/news/medtech-trends-outlook-2026/810902/

    https://www.biospace.com/press-releases/nona-biosciences-co-founds-innovative-alliance-for-translational-medicine-in-immunological-diseases-advancing-a-new-iit-driven-ecosystem

    https://www.biospace.com/press-releases/stellaromics-expands-pyxa-3d-spatial-transcriptomics-beta-program-with-installation-at-emory-university-school-of-medicine

    https://www.biospace.com/press-releases/cmuh-ever-supreme-team-develops-world-first-brain-targeting-exosome-delivering-curcumin-across-the-blood-brain-barrier-for-parkinsons-disease

    https://www.pharmexec.com/view/daily-disconnect-between-pharma-medtech

    https://pharmaphorum.com/digital/ais-promise-biotechs-peril-how-unequal-access-computing-power-threatens-medical

    https://www.genengnews.com/topics/translational-medicine/barbados-government-and-biomed-x-partner-to-improve-ai-based-early-diabetic-kidney-disease-modeling
  • The Patient Signal

    Neuralink's Telepathy Trials, BD-Waters Merger, AI Street Medicine, and Boehringer's Kidney Breakthrough

    29/01/2026 | 8 min
    In this episode, we delve into Neuralink's groundbreaking clinical trials with 21 "Neuralnauts" using the Telepathy device, allowing quadriplegics to control devices through thought. We also cover BD and Waters' $17.5 billion merger, set to double Waters' market reach. Phacilitate's Advanced Therapies Week 2026 highlights cell and gene therapy advancements amid regulatory challenges. Minaris enhances its Viral Clearance lab in Philadelphia, boosting efficiency for cell and gene therapies. Akido Labs launches an AI-powered street medicine program in the Bay Area to aid the homeless. iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare disease research. Lastly, Boehringer Ingelheim's apecotrep shows promise in treating a rare kidney disease, marking a significant step in their kidney disorder pipeline.

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    📚 Sources:

    https://teslanorth.com/2026/01/28/from-paralysis-to-neuroscience-how-21-people-are-using-neuralink-in-2026/

    https://www.medtechdive.com/news/bd-water-merger-completion-date/810678/

    https://www.biospace.com/drug-development/advanced-therapies-week-2026-solving-for-science-and-weathering-global-complexity

    https://www.biospace.com/press-releases/minaris-announces-viral-clearance-laboratory-upgrade-at-philadelphia-campus

    https://www.fiercehealthcare.com/providers/akido-labs-partners-launch-ai-powered-street-medicine-program-bay-area

    https://www.genengnews.com/topics/translational-medicine/ix-cells-and-rosebud-biosciences-partner-on-organoid-based-rare-disease-models

    https://pharmaphorum.com/news/boehringer-drug-scores-rare-kidney-disease-fsgs

Más podcasts de Ciencias

Acerca de The Patient Signal

Healthcare innovation is moving fast, but are we leaving the patient behind? The Patient Signal is the essential briefing for patient advocates, policymakers, and health tech innovators who need to understand the human impact of new technology. We move beyond the hype of funding rounds and stock prices to focus on what matters most: access, outcomes, and equity. Each episode breaks down the critical intersection of Artificial Intelligence, Life Sciences, and Government Policy. We filter the noise to find the specific tools and regulations that are changing the patient journey right now. If you are building the future of care or fighting for those who need it, this is your signal. What we cover: Health Policy: New CMS rulings and legislative updates affecting access. AI Innovation: Practical tools for diagnostics and remote care. Advocacy: Victories and challenges from the patient community.
Sitio web del podcast

Escucha The Patient Signal, ¿Y si todo esto es mentira? y muchos más podcasts de todo el mundo con la aplicación de radio.net

Descarga la app gratuita: radio.net

  • Añadir radios y podcasts a favoritos
  • Transmisión por Wi-Fi y Bluetooth
  • Carplay & Android Auto compatible
  • Muchas otras funciones de la app

The Patient Signal: Podcasts del grupo

Aplicaciones
Redes sociales
v8.8.6| © 2007-2026 radio.de GmbH
Generated: 4/5/2026 - 4:14:58 PM